Aveanna Healthcare vs Chemed
AVAH and CHE side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVAH and CHE compare
Chemed is the larger company, worth 2.4 times as much as Aveanna Healthcare ($7.0B against $2.9B).
On earnings, Aveanna Healthcare is cheaper: it trades at 10.7× trailing earnings, against 25.6× for Chemed.
Aveanna Healthcare grew revenue faster over the last twelve months (19.5% versus 5.2% for Chemed).
Chemed keeps more of each dollar of sales as profit, with a net margin of 10.6% compared with 10.6% at Aveanna Healthcare.
Chemed pays a dividend yielding 0.47%; Aveanna Healthcare does not pay one.
Chemed scores higher on the StockData Score (17 against 11 for Aveanna Healthcare), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVAH | CHE |
|---|---|---|
| Size and price | ||
| Market cap | $2.9B | $7.0B |
| Share price | $13.16 | $534.72 |
| Change, 1 year | 33.5% | 14.9% |
| Change, 5 years | 57.4% | 7.7% |
| Beta (5Y) | 1.41 | 0.35 |
| Employees | 32K | 16K |
| StockData Score | ||
| Total score | 11 | 17 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 | 4 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 10.7× (better) | 25.6× |
| P/S | 1.1× (better) | 2.6× |
| P/B | 10.0× | 8.1× (better) |
| EV/EBITDA | 14.3× (better) | 16.4× |
| P/FCF | – | 23.7× |
| PEG | – | 7.26 |
| FCF yield | – | 4.2% |
| Fair value | $22.07 | $515.29 |
| Margin of safety | 40.4% (better) | −3.8% |
| Growth | ||
| Revenue growth (TTM) | 19.5% (better) | 5.2% |
| Revenue growth, 5Y average | 10.2% (better) | 4.0% |
| Net income growth (TTM) | 1381% (better) | 1.3% |
| EPS growth (TTM) | 1267% (better) | 10.5% |
| EPS growth, 5Y average | – | −1.2% |
| Profitability | ||
| Gross margin | 32.3% | 33.5% (better) |
| Operating margin | 10.5% | 13.9% (better) |
| Net margin | 10.6% | 10.6% (better) |
| FCF margin | – | 11.1% |
| Return on equity | 200% (better) | 29.1% |
| Return on invested capital | 20.6% | 27.4% (better) |
| Financial health | ||
| Debt / equity | 4.52 | 0.27 (better) |
| Net debt / EBITDA | 4.21 | 0.43 (better) |
| Interest coverage | 2.2× | 75.4× (better) |
| Current ratio | 1.16 (better) | 1.11 |
| Altman Z-score | 1.94 | 9.73 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.47% |
| Payout ratio | – | 11.9% |
| Years of dividend growth | – | 16 |
| Dividend growth, 5Y average | – | 10.8% |
| Buyback yield | – | 7.5% |
| Shareholder yield | 0.00% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 93.0% | 104% |
| Held by insiders | 16.9% | 1.3% |
| Insider net buying, 12 months | −$782M | −$8.8M (better) |
| Short interest, % of float | 3.1% | 4.6% |
Go deeper
- AVAH stock overview
- AVAH income statement
- AVAH valuation and score
- CHE stock overview
- CHE income statement
- CHE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.